Bristol Unveils Post-Celgene Leadership Team, With Big R&D Changes
Novartis's Hirawat will join the company as chief medical officer, while Celgene's Vessey will head early research. Bristol's current chief scientific officer Lynch will leave the company in October.
You may also be interested in...
Nearly One Year Post-Celgene: BMS CMO On Pipeline Progress, Clinical Trial Diversity
Chief medical officer Samit Hirawat outlines R&D successes – though there have been some setbacks since it bought Celgene for $74bn last year – and the company’s commitment to clinical trial diversity.
Novartis' New Oncology CEO Schaffert Has A Potential Blockbuster Launch On Her Hands
In an interview at Novartis' research campus in Cambridge, Mass., Schaffert spoke about the upcoming launch of Piqray for breast cancer, building in radiopharmaceuticals, Kymriah's ongoing manufacturing challenges and more.
As Expected: Shareholders Back Bristol's $74bn Celgene Buy
With no more activist investor challenge, shareholders of both companies overwhelmingly approved the deal. Bristol said it will have leading positions in oncology and cardiovascular disease, and gain five potential blockbusters in the Celgene buyout.